Pure Global: Brazil's SaMD Cyber Shock—Cracking ANVISA's Hidden Compliance Traps

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for manufacturers aiming to enter or remain in Latin America's largest market. We uncover the specific documentation now required and explain why your existing FDA or CE marking might not be enough. This episode delves into the real-world impact of these changes. Imagine your state-of-the-art health app, already successful in the U.S. and Europe, is suddenly halted at the Brazilian border. Your dossier is rejected for failing to meet new, highly specific cybersecurity criteria. This is the new reality for many, causing costly delays and demanding a complete overhaul of regulatory strategy. Key questions answered in this episode: - What are the three critical documents ANVISA now demands for SaMD cybersecurity? - How can you leverage your existing international documentation for the new Brazilian requirements? - Is on-the-ground cybersecurity testing now mandatory in Brazil? - What are the most common pitfalls leading to dossier rejection under the new framework? - How can proactive post-market surveillance protect you from a product recall? - Does the new rule apply to legacy devices already on the market? - How will this impact the timeline and cost of entering the Brazilian market? Struggling with global market access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI to streamline market entry. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.